References

1. Allergan Inc., Press Releases on Memantine Trials, Fourth Quarter Operating Results, 30 Jan 2008.

2. T. Krupin et al., Am. J. Ophthalmol., 2011;151:671–681.

3. J. Mey and S. Thanos, Brain Res., 1993;602(2):304–317.

4. S. Mansour-Robaey et al., Proc. Natl. Acad. Sci. USA, 1994;91:1632–1636.

5. P. Peinado-Ramon et al., Invest. Ophthalmol. Vis. Sci., 1996;37:489–500.

6. N. Klocker et al., J. Neurosci., 2000;20:6962–6967.

7. H. Chen and A.J. Weber, Invest. Ophthalmol. Vis. Sci., 2001;42:966–974.

8. M.L. Ko et al., Neurosci. Lett., 2001;305:139–142.

9. A. Di Polo et al., Proc. Natl. Acad. Sci. USA, 1998;95:3978–3983.

10. L. Cheng et al., J. Neurosci., 2002;22:3977–3986.

11. K.R. Martin et al., Invest. Ophthalmol. Vis. Sci., 2003;44:4357–4365.

12. Q. Yan et al., J. Neurobiol., 1999;38:382–390.

13. P.D. Koeberle and A.K. Ball, Vision Res., 1998;38:1505–1515.

14. A. Lambiase et al., Proc. Natl. Acad. Sci. USA, 2009;106(32):13469–13474.

15. Y. Zhang et al., FEBS Lett., 2008;582:956–960.

16. N.P. Visanji et al., FASEB J., 2008;22(7):2488–2497.